Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting KRAS in cancer
Anupriya Singhal, Bob T. Li, Eileen M. O’Reilly
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 969-983
Closed Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Carter Norton, Matthew Shaw, Zachary Rubnitz, et al.
JAMA Network Open (2025) Vol. 8, Iss. 1, pp. e2453588-e2453588
Open Access | Times Cited: 2
Consensus, debate, and prospective on pancreatic cancer treatments
Junke Wang, Jie Yang, Amol Narang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 11
Binding Affinity Determination in Drug Design: Insights from Lock and Key, Induced Fit, Conformational Selection, and Inhibitor Trapping Models
Danislav S. Spassov
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7124-7124
Open Access | Times Cited: 8
A stumbling block in pancreatic cancer treatment: drug resistance signaling networks
Jinming Liu, Biao Zhang, Bingqian Huang, et al.
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access | Times Cited: 1
Digestive cancers: mechanisms, therapeutics and management
Tianzuo Zhan, Johannes Betge, Nadine Schulte, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 1
High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer in vitro and in vivo models
Hak Su Kim, Seunghyun Kwon, Ok Kyung Choi, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Treatment patterns and outcomes in KRAS‐positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study
Samir H. Barghout, Luna Jia Zhan, Starvroula Raptis, et al.
Lung Cancer (2024) Vol. 194, pp. 107898-107898
Closed Access | Times Cited: 6
Novel Tricyclic KRAS Inhibitors for the Treatment of Cancer
Tao-Qian Zhao, Steven H. Liang
ACS Medicinal Chemistry Letters (2025) Vol. 16, Iss. 2, pp. 178-179
Open Access
Not all KRAS-mutated pancreatic cancers are equal — mutant dosage matters

Nature Medicine (2025)
Closed Access
HSF1 at the crossroads of chemoresistance: from current insights to future horizons in cell death mechanisms
Shruti Ghai, Rejina Shrestha, Kuo‐Hui Su
Frontiers in Cell and Developmental Biology (2025) Vol. 12
Open Access
The Current Role of Circulating Tumor DNA in the Management of Pancreatic Cancer
M.C. Cox, Dominic Vitello, Akhil Chawla
Journal of Gastrointestinal Cancer (2025) Vol. 56, Iss. 1
Closed Access
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Jian Zou, Wei Han, Yan Hu, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Five Key Criteria for Identifying Optimal Therapeutic Targets in Protein‐Mediated Diseases
Mohammed Baqur S. Al‐Shuhaib, Jafar M. B. Al‐Shuhaib
ChemistrySelect (2025) Vol. 10, Iss. 4
Closed Access
A safe haven for cancer cells: tumor plus stroma control by DYRK1B
Miriam Ems, Anna Brichkina, Matthias Lauth
Oncogene (2025)
Open Access
Targeting ferroptosis: a promising approach for treating lung carcinoma
Ziyang Wu, Tao Zhang, Wei Zhong, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Acid-Cleavable Guanosine Triphosphate-Photoaffinity Probe for Global Profiling of Guanosine Triphosphate-Binding Proteins and Their Active Sites
Can Gao, Mengxuan Li, Jing Tan, et al.
Analytical Chemistry (2025)
Closed Access
Oncogenic RIT1 mutations confer ferroptosis vulnerability in lung adenocarcinoma
Ruilan Ma, Dian Yang, Peng Wang, et al.
Biology Direct (2025) Vol. 20, Iss. 1
Open Access
A prognostic signature of Glutathione metabolism-associated long non-coding RNAs for lung adenocarcinoma with immune microenvironment insights
Junxi Hu, Shuyu Tian, Qingwen Liu, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRASG12C Inhibitors in Nonsmall Cell Lung Cancer
Zehao Pan, Yuxian Qian, Yajing Wang, et al.
Cancer Science (2025)
Open Access
KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC
Xiangyan Jiang, Tao Wang, Bin Zhao, et al.
Cell Reports Medicine (2025) Vol. 6, Iss. 2, pp. 101966-101966
Open Access
Reducing pERKs to Break “RAS”istance to Sotorasib
Steven G. Gray, Derbrenn O'Connor, Luciano Mutti, et al.
Journal of Thoracic Oncology (2025) Vol. 20, Iss. 3, pp. 259-261
Closed Access
Drugging Challenging Cancer Targets Using Fragment-Based Methods
Stephen W. Fesik
Chemical Reviews (2025)
Open Access
Page 1 - Next Page

Scroll to top